HK1140480A1 - Cysteine protease inhibitors - Google Patents

Cysteine protease inhibitors

Info

Publication number
HK1140480A1
HK1140480A1 HK10106881.7A HK10106881A HK1140480A1 HK 1140480 A1 HK1140480 A1 HK 1140480A1 HK 10106881 A HK10106881 A HK 10106881A HK 1140480 A1 HK1140480 A1 HK 1140480A1
Authority
HK
Hong Kong
Prior art keywords
protease inhibitors
cysteine protease
cysteine
inhibitors
protease
Prior art date
Application number
HK10106881.7A
Other languages
English (en)
Inventor
Magnus Nilsson
Lourdes Oden
Pia Kahnberg
Urszula Grabowska
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of HK1140480A1 publication Critical patent/HK1140480A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK10106881.7A 2007-06-27 2010-07-15 Cysteine protease inhibitors HK1140480A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92943707P 2007-06-27 2007-06-27
EP07123771 2007-12-20
PCT/EP2008/058136 WO2009000877A1 (en) 2007-06-27 2008-06-26 Cysteine protease inhibitors

Publications (1)

Publication Number Publication Date
HK1140480A1 true HK1140480A1 (en) 2010-10-15

Family

ID=40020008

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10106881.7A HK1140480A1 (en) 2007-06-27 2010-07-15 Cysteine protease inhibitors

Country Status (19)

Country Link
US (3) US7893067B2 (xx)
EP (1) EP2167507B1 (xx)
JP (1) JP5501961B2 (xx)
KR (1) KR101552150B1 (xx)
CN (1) CN101687880B (xx)
AR (1) AR067363A1 (xx)
AU (1) AU2008267166B2 (xx)
BR (1) BRPI0813763A2 (xx)
CA (1) CA2690344C (xx)
DK (1) DK2167507T3 (xx)
EA (1) EA017395B1 (xx)
ES (1) ES2573229T3 (xx)
HK (1) HK1140480A1 (xx)
MX (1) MX2009013789A (xx)
MY (1) MY149191A (xx)
PL (1) PL2167507T3 (xx)
TW (1) TWI419893B (xx)
WO (1) WO2009000877A1 (xx)
ZA (1) ZA200908771B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893067B2 (en) 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
GB0817424D0 (en) * 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
WO2010137944A1 (en) 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013079A1 (es) 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
JP2004520439A (ja) 2000-11-17 2004-07-08 メディヴィル・アクチボラグ システインプロテアーゼインヒビター
AU2002219397B2 (en) 2001-01-17 2008-02-14 Grünenthal GmbH Inhibitors of cruzipain and other cysteine proteases
CN100548986C (zh) 2003-12-12 2009-10-14 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
WO2005065578A2 (en) 2004-01-06 2005-07-21 Nicast Ltd. Vascular prosthesis with anastomotic member
DE602005019971D1 (de) 2004-01-08 2010-04-29 Medivir Ab Inhibitoren von cysteinprotease
CN1910175A (zh) 2004-01-08 2007-02-07 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
GB0513839D0 (en) 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0614052D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
US7893067B2 (en) * 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
GB0804702D0 (en) * 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
CN101687880B (zh) 2012-09-05
EA017395B1 (ru) 2012-12-28
PL2167507T3 (pl) 2016-09-30
ZA200908771B (en) 2011-04-28
TW200911818A (en) 2009-03-16
JP5501961B2 (ja) 2014-05-28
EP2167507A1 (en) 2010-03-31
MX2009013789A (es) 2010-02-01
CA2690344A1 (en) 2008-12-31
AR067363A1 (es) 2009-10-07
US20120220602A1 (en) 2012-08-30
EA201070062A1 (ru) 2010-08-30
US8198283B2 (en) 2012-06-12
EP2167507B1 (en) 2016-03-02
CA2690344C (en) 2015-06-02
BRPI0813763A2 (pt) 2014-12-30
US20110105524A1 (en) 2011-05-05
US7893067B2 (en) 2011-02-22
ES2573229T3 (es) 2016-06-06
AU2008267166B2 (en) 2011-04-21
MY149191A (en) 2013-07-31
KR20100040879A (ko) 2010-04-21
CN101687880A (zh) 2010-03-31
JP2010531336A (ja) 2010-09-24
AU2008267166A1 (en) 2008-12-31
US20090023748A1 (en) 2009-01-22
TWI419893B (zh) 2013-12-21
KR101552150B1 (ko) 2015-09-10
US8466158B2 (en) 2013-06-18
WO2009000877A1 (en) 2008-12-31
DK2167507T3 (en) 2016-06-13

Similar Documents

Publication Publication Date Title
LTC2178888I2 (lt) Proteazomos inhibitoriai
HK1148739A1 (en) Hcv protease inhibitors hcv
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
EP2139883A4 (en) INHIBITORS OF HIV-1 PROTEASE
HK1127351A1 (zh) 抗病毒蛋白酶抑制劑
GB0513841D0 (en) Cysteine protease inhibitors
EP2064177A4 (en) PROTEASE INHIBITORS
EP2509956A4 (en) INHIBITORS OF CYSTEINE PROTEASES
EP2358692A4 (en) CYSTEINE PROTEASE INHIBITORS
EP2313426A4 (en) NOVEL PROTEASE INHIBITORS
EP2134336A4 (en) HIV PROTEASE INHIBITORS DERIVED FROM BENZOFURAN
ZA201102179B (en) Protease inhibitors
HK1140480A1 (en) Cysteine protease inhibitors
GB0513840D0 (en) Cysteine protease inhibitors
GB0513839D0 (en) Cysteine protease inhibitors
EP2139876A4 (en) CYSTEINE INHIBITORS OF CATHEPSIN TYPE PROTEASES
GB0817425D0 (en) Protease inhibitors
GB0712541D0 (en) Cysteine protease inhibitors
GB0712222D0 (en) Cysteine protease inhibitors
GB0703043D0 (en) Cysteine protease inhibitors
GB0724732D0 (en) Cysteine protease inhibitors
GB0712172D0 (en) Cysteine protease inhibitors
GB0712193D0 (en) Cysteine protease inhibitors
GB0712540D0 (en) Cysteine protease inhibitors
EP2168954A4 (en) CYSTEINE PROTEASES INHIBITORS

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180626